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Objective: Haematopoietic stem cell transplantation (HSCT) is
frequently complicated by early Human herpesvirus type 6
(HHV6) reactivation and is associated with poor survival and severe
acute Graft-versus-host-disease (aGvHD). We hypothesized that
HHV6may be a trigger for immunedysregulation, resulting in allor-
eactivity. We investigated total T-cell numbers and HHV6-specific
Interferon-g (IFNg) producing T-cells in children with or without
HHV6-reactivation after HSCT using a newly developed enzyme-
linked immunospot (ELISPOT) technique.
Methods: Prospectively, HHV6, Cytomegalovirus, Adenovirus
and Epstein Barr virus DNA-loads were weekly monitored by quan-
titative realtime-PCR and clinical data were collected. HHV6 reac-
tivation was defined as HHV6 DNA-load .250cp/mL. T-cell
reconstitution was prospectively measured every other week by im-
munophenotyping (markers CD3, CD4 and CD8). Numbers of
IFNg-producingT-cells in PBMCswere retrospectively determined
by ELISPOT after overnight stimulation with HHV6-virus lysate
(ABI, Columbia, Maryland, USA) 2 months after HSCT.
Results: Twenty-one HSCT patients were analyzed (median age
4.4 years; range 1–16.5yrs). Within the first two months, 13/21
(62%) patients developed HHV6 reactivation; median time of reacti-
vation was 14 (range 1–41) days. The development of other virusreac-
tivations did not differ between the two groups; 4/13 versus 3/8
respectively. The median number of IFNg-producing specific
HHV6 T-cells 2 months after HSCT was significantly increased in
the patients with HHV6-reactivation; 40 (0–362) versus 0 (0–25) spe-
cificT-cells permillionPBMCs (p5 0.006). Additionally, themedian
CD31 T-cell numbers were significantly increased in these patients;
393 (32–5514) versus 93 (0–641) T-cells/uL (p5 0.03), includingme-
dian CD81 T-cells; 79% (6–87 %) versus 33% (0–83%) (p5 0.03).
Conclusions: Patients with HHV6 reactivation had significantly
higher numbers of IFNg-producing HHV6-specific T-cells and
more CD31T-cells/uL, among which mainly CD81T-cells. Given
the association of HHV6 reactivation and aGvHD, these T-cells
may be alloreactive.393
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Background: Haematopoietic stem cell transplantation (HSCT)
is frequently complicated by human herpesvirus 6 (HHV6), cyto-
megalovirus (CMV) or Epstein Barr virus (EBV) reactivations. Her-
pesvirusreactivations are associated with severe morbidity and
mortality after HSCT. Although T-lymphocytes play an important
role in the clearance of viral reactivations after HSCT, an easy mea-
sure of potent T-cell responses for predicting outcome of viral reac-
tivations is lacking. We analyzed expression of perforin (a cytolytic
pore-forming protein) as a marker for cytotoxic potential in
CD81T-cells in children and related this to the clearance of viral re-
activations after HSCT.
Methods: In a prospective cohortstudy (2007–2008), we weekly
monitored HHV6, CMV and EBV DNA loads in plasma after
HSCT by quantitative realtime PCR. Herpesvirus reactivation was
defined as DNA load .1000 cp/mL. CMV- and EBVreactivation
were treated according to local guidelines. HHV6reactivation was
treated when there was clinical suspicion of disease. We have weekly
analyzed Perforin expression in CD81T-cells by whole blood FAC-
Sanalysis, until 4 months after HSCT.
Results: A total of 27 patients were included with a median age of
4.3 (range 0.3–20.1) years. 15/27 (56%) recipients received bone-
marrow (7/15 from matched family donors) or unrelated peripheral
blood stemcells while 12/27 (44%) recipients received unrelated
cordblood stemcells. All patients received myeloablative condition-
ing and standardized Graft-versus-host disease prophylaxis. During
the first 4 months after HSCT, 16 patients developed HHV6reacti-
vation, 2 patients developed CMVreactivation and 1 patient devel-oped EBVreactivation. The median time of herpesvirusreactivation
peak was 2.4 weeks (range 1.3–15.6) after HSCT. Viral clearance
was marked by a perforin peak in CD81 T-cells; median time of
maximum perforin expression in CD81T-cells was 4 weeks (range
1.4–15.9) after HSCT. Patients with herpesvirusreactivation
(HHV6, CMVorEBV) showed significantly higher perforin-expres-
sion in CD81T-cells during viral load clearance than patients with-
out herpesvirusreactivation (17.2% (range 0–63%) versus 6.8%
(range 0–16%); p 5 0.003).
Conclusion: Herpesvirus reactivation clearance was significantly
associated with a peak in perforin-expressing CD81T-cells. Al-
though virus-specific immune responses after HSCT have to be elu-
cidated, perforin expression in T-cells is a useful marker for antiviral
T-cell responses and viral load clearance after HSCT.
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NK cells play a significant role in tumor cell recognition and cyto-
toxicity (Trinchieri et al Adv Immunol, 1990). NKG2D-mediated
recognition of malignant cells by NK cells is enabled through the tu-
mor-associated expression of NKG2DL. Among these NKG2DL,
MIC A and B are significantly expressed on epithelial compared to
hematological tumors (Bauer et al Science, 1999). Skov et al (Cancer
Res, 2005) demonstrated a significant increase in surface expression
of MIC A and B in various epithelial cancer cell lines after exposure
toHDACi.We compared the expression of NKG2DLMICA and B
in common pediatric hematological tumor cell lines and the impact
of enhanced expression of NKG2DL on NK cell mediated cytotox-
icity. Cell lines used were: ALL (SUP-B15, RS 4:11, REH, Jurkat),
NHL (Toledo, Ramos). Cells were co-cultured for 24hrs with 0, 5
and 10ng/ml of Romidepsin. MICA/B PE antibody was used for
flow cytometry staining. Purified adult peripheral blood NK
(CD561/3-) cells and IL-2 activated NK cells (12hr incubation)
were added to target cells (cultured with 5–10ng/ml of Romidepsin
x 24hrs) at effector to target ratio of 5:1 and 10:1 and incubated
for 2hrs. NK cell cytotoxicity was determined by a standard euro-
pium assay. There was a significant increase in expression of
MICA/B in ALL cell lines when co-cultured with Romidepsin at
10ng/ml (RS 4:11 0.2% vs 19.2% p\0.0001, REH 0.2% vs 46%
p 5 0.0003, Jurkat 1.12% vs 44.7% p\0.0001). We also noted sig-
nificant increase in MICA/B in some NHL cell lines when co-
cultured with Romidepsin at 10ng/ml (Toledo [DLBCL] 0.5% vs
15.8% p5 0.0001, Ramos [BL] 0.57% vs 33.6% p5 0.0003). There
was significant increase in vitro cytotoxicty in RS 4:11 cells at E:T
ratio of 5:1 and 10:1 (5:1 specific release: RS 4:11 cells1NK cells
vs. RS 4:11 cells1IL-2 activatedNK cells vs. RS 4:11 cells1NK cells
with 10ng/ml of Romidepsin vs. RS 4:11 cells1IL-2 activated NK
cells with 10ng/ml of Romidepsin was 3.3% vs 6% vs 45% vs
61.6% p\0.01, and at 10:1 ratio 9.3% vs 10.6% vs 71.6% vs
86.3% p\0.05, respectively). In summary, these results suggest
that Romidepsin induces significant expression of MICA/B ligands,
enhancing their susceptibility for NKG2D-mediated cytotoxicity by
NK cells. The combination of Romidepsin and NK cells presents
a potential for ACI. Future studies will be conducted with MIC A
and B antibodies to determine the specificity of the Romidepsin ef-
fect and the invivo cytotoxicity in a human/mouse xenograft SCID
model.395
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